EU issues first-ever pharmaceutical cartel decision

Boehringer Ingelheim and five other drugmakers have agreed to pay the European Commission €13.4 million in a hybrid settlement decision after admitting to participating in a global cartel to fix the price of an essential stomach medicine.

Unlock unlimited access to all Global Competition Review content